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REVIEW
Abstract: Erectile dysfunction (ED) is a highly prevalent disease associated with aging as 
well as with several risk factors including hypertension, heart disease, obesity, dyslipidemia, 
diabetes, hypogonadism, drugs-related, and pelvic surgery. Many of these factors are compo-
nents of the metabolic syndrome, a multiplex risk factor for cardiovascular disease (CVD). ED 
shares common risk factors with CVD. Endothelial dysfunction seems to be the early underlying 
pathophysiology across both conditions. The efﬁ  cacy, tolerability and cardiovascular safety of 
sildenaﬁ  l has been evaluated in numerous large, randomized, double-blind, placebo-controlled 
clinical studies in the broad population of men with ED including men with several co-morbid 
conditions. Sildenaﬁ  l is effective in several speciﬁ  c patient populations including the difﬁ  cult-to-
treat subpopulations such as diabetes mellitus and after radical prostatectomy. It is associated 
with rapid onset of action – within 14 minutes for some men – and an extended duration of 
action for up to 12 hours. Sildenaﬁ  l improves quality of life and satisfaction for treated men and 
is well tolerated with a favorable safety proﬁ  le. New data suggest that sildenaﬁ  l has beneﬁ  cial 
effects in several chronic conditions. It has been approved for the treatment of idiopathic 
pulmonary hypertension. Numerous articles have suggested that it improves endothelial func-
tion and a possible role on premature ejaculation or treatment of lower urinary tract symptoms 
has been suggested.
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Introduction
Erectile dysfunction (ED) is a highly prevalent disease, as well as a major sexual 
concern for men (Braun et al 2000; Martin-Morales et al 2001; Papaharitou et al 
2006). The prevalence of ED is increasing with age. The Massachusetts Male 
Aging Study (MMAS) demonstrated a 40% prevalence of ED in men aged 40 years 
that increased to almost 70% in men aged 70 years (Feldman et al 1994). As the 
proportion of older people in the population increases, it has been estimated that 
the worldwide prevalence of ED will double from 152 million men in 1995 to 
322 million men in 2025 (Aytac et al 1999). ED is also associated with other 
conditions such as age, smoking, hypertension, heart disease, diabetes, and as a 
consequence of radical prostatectomy. Cardiovascular disease (CVD) and ED share 
common risk factors and reﬂ  ect endothelial dysfunction (Kostis et al 2005). There 
is an increasing body of evidence that ED is the ﬁ  rst sign of CVD in men with 
free medical history and may present well before CVD with a mean time-interval 
of even 3 years (Montorsi et al 2003).
The availability of phosphodiesterase type 5 inhibitors (PDE5i) has resulted in 
increasing numbers of patients seeking medical help for erectile function problems, 
but has also altered dramatically the medical management of ED (Hatzichristou 
and Pescatori 2001; Lewis et al 2001; Steers et al 2001). More physicians are 
treating ED, especially in the primary care setting, including minimal patient 
work-up and prescription of PDE5i due to their proven efﬁ  cacy and safety proﬁ  le. 
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The management of ED by non-specialists includes minimal 
patient work-up and prescription of exclusively ﬁ  rst-line 
treatment options in most cases, mainly due to the lack 
of time and background knowledge (Hatzichristou 2002). 
Sildenaﬁ  l was the ﬁ  rst available PDE5i that revolutionized 
ED treatment (Goldstein et al 1998). More than 30 million 
of men are treated worldwide with sildenaﬁ  l accompanied 
by vast experience and research with more than 2600 papers 
published in Medline as of July 2006. Furthermore, new data 
suggest that sildenaﬁ  l has beneﬁ  cial effects in several chronic 
conditions. It has been recently approved for the treatment 
of idiopathic pulmonary hypertension (Galie et al 2005), 
and numerous articles have suggested that PDE5i may 
improve endothelial function (Katz et al 2000; Desouza 
et al 2002; Halcox et al 2002; Vlachopoulos et al 2003; 
Vlachopoulos et al 2004; Gori et al 2005; Hirata et al 
2005). PDE5i have been also suggested to be beneﬁ  cial 
for patients with premature ejaculation (Abdel-Hamid 
2004). However, clinical studies have shown controversial 
results so far (Salonia et al 2002; Chen et al 2003; Atan 
et al 2006) and it remains uncertain, whether PDE5i act 
on the physiologic process of ejaculation, or indirectly, 
improving erectile function and therefore, reducing per-
formance anxiety in men with ED.
The aim of this review is to provide an overview of the 
clinical evidence associated with sildenaﬁ  l in the treatment of 
ED as well as to present data from ongoing basic and clinical 
research in other chronic diseases.
Pharmacological proﬁ  le: time 
to onset and duration of action
Sildenafil is a highly selective inhibitor of PDE type 5 
(Boolell et al 1996; Gbekor et al 2002). It enhances 
NO-mediated relaxation of human corpus cavernosum 
in vitro (Ballard et al 1998; Stief et al 1998; Gemalmaz 
et al 2001). Sildenafil, by inhibiting phosphodiesterase, 
increases the intracellular concentrations of cyclic 
guanosine 3’,5’ monophosphate (cGMP), causing an 
amplification of the endogenous NO-cGMP signaling 
pathway.
The time to maximum plasma concentration is about 1 h 
while the plasma half-life is about 4–5 h. It is administered 
orally on demand in 25 mg, 50 mg, and 100 mg doses. The 
recommended starting dose is 50 mg and adapted according 
to efﬁ  cacy and tolerability. Patients are instructed to take 
sildenaﬁ  l approximately 1 h before sexual intercourse with a 
maximum dosing frequency of once daily. Sexual stimulation 
is a prerequisite for sildenaﬁ  l as well as for the other PDE5i. 
The window of opportunity to engage in sexual intercourse 
is maintained from 30 min to 4–5 h from administration. 
However, the onset of action can be 14 min for about 35% 
of patients (Figure 1) (Padma-Nathan et al 2003) and ef-
ﬁ  cacy may be maintained for up to 12 h (Moncada et al 
2004). A heavy fatty meal results in reduced and prolonged 
absorption. Alcohol does not have an impact on absorption 
in regular doses. Contraindications for the use of sildenaﬁ  l 
and need for dose adjustments are summarized in Table 1 
(Langtry and Markham 1999). 
Efﬁ  cacy in broad populations 
of men with ED
The ﬁ  rst data on efﬁ  cacy of sildenaﬁ  l were published by 
Goldstein and colleagues (1998) Sexual intercourse was 
Figure 1 Time to onset of erection resulting in successful intercourse. *P=0.0343, 
†P=0.0011, ‡P=0.0001. Copyright © 2003. Reproduced with permission from 
Padma-Nathan H, Stecher VJ, Sweeney M, et al. 2003. Minimal time to successful
intercourse after sildenaﬁ  l citrate: results of a randomized, double-blind, 
placebo-controlled trial. Urology, 62:400-3.
Abbreviations: SEP3, Sexual Encounter Proﬁ  le question 3.
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Table 1 Contraindications and dose adjustments for sildenaﬁ  l 
(as well as for the other phosphodiesterase type 5 inhibitors)
Absolute contraindications 
Concomitant use of nitrates 
Medications / conditions requiring lower doses 
Ketoconazole  
Itraconazole 
Erythromycin, 
Clarithromycin  
HIV protease inhibitors (ritonavir, saquinavir) 
Severe kidney dysfunction  
Severe hepatic dysfunction 
Medications / conditions requiring higher doses 
Rifampin 
Phenobarbital 
Phenytoin  
Carbamazepine Clinical Interventions in Aging 2006:1(4) 405
Sildenaﬁ  l in the treatment of erectile dysfunction
successful in 69% of all attempts for the men receiving 
sildenaﬁ  l, as compared with 22% for those receiving 
placebo (p<0.001). The mean numbers of successful at-
tempts per month were 5.9 for men receiving sildenaﬁ  l and 
1.5 for those receiving placebo (p<0.001). Efﬁ  cacy param-
eters for sildenaﬁ  l in 11 double-blind, placebo controlled, 
pre-marketing studies included the International Index of 
Erectile Function (IIEF) erectile function domain score 
and especially the questions 3 and 4 (ability to attain and 
ability to maintain an erection sufﬁ  cient for intercourse 
respectively) as well as the general efﬁ  cacy question 
(GEQ). In 6 of the 11 trials, patients maintained an event 
log of sexual activity. Patients were stratiﬁ  ed in subgroups 
in terms of age, race, body mass index (BMI), duration of 
ED, ED etiology, smoking status, and concomitant con-
ditions/medications (Figure 2). All subgroups were well 
balanced between placebo and sildenaﬁ  l. After 12 weeks 
of treatment, 46.5% to 87% of patients in the subgroups 
receiving sildenaﬁ  l indicated that treatment had improved 
their erections compared with 11.3% to 41.3% of patients 
in subgroups receiving placebo. In the 6 trials in which 
sexual event log data were collected, signiﬁ  cantly greater 
percentages of successful attempts at intercourse were 
reported by patient subgroups receiving sildenaﬁ  l (52.6% 
to 80.1%) compared with patient subgroups receiving 
placebo (14.0% to 34.5%). All differences were statisti-
cally signiﬁ  cant (Carson et al 2002).
Long-term effectiveness of sildenaﬁ  l was assessed in 
3 open-label, ﬂ  exible-dose (25 mg to 100 mg) studies. After 
12 months of treatment (3 years in one study) or at the time 
of discontinuation, patients were asked if they were satisﬁ  ed 
with the effect of the medication on erections, and if the 
treatment improved their ability to engage in sexual activity. 
Satisfaction and improvement in ability to engage in sexual 
activity reported in 96% and 99% of patients respectively. 
Of the 11% of patients who discontinued treatment, 2% 
discontinued for treatment-related reasons (1.6% for insuf-
ﬁ  cient response, 0.4% for adverse events). These satisfaction 
rates maintained for 3 years in one study. Over the 3-year 
period, 32% of patients discontinued treatment. Only 6.7% 
of discontinuations were treatment related (5.7% for insuf-
ﬁ  cient response, 1% for treatment-related adverse events). 
The remaining 25.3% of patients discontinued for reasons 
not related to treatment (eg, non–treatment-related adverse 
events, lost to follow-up evaluation, withdrawn consent, and 
protocol violations). Most patients were receiving 100 mg 
sildenaﬁ  l doses (88% at 3 years) (Carson et al 2002). Similar 
efﬁ  cacy rates for sildenaﬁ  l were reported in clinical practice 
setting. An improvement in ability to achieve erections 
was reported by 68% and 71% of patients with ED (Marks 
et al 1999; McMahon et al 2000). Success with sildenaﬁ  l, 
deﬁ  ned as 75% successful intercourse, was reported by 
82% of patients with 77% being successful at every attempt 
(Guay et al 2001).
Figure 2 Mean score for the Sexual Encounter Proﬁ  le question 3 (SEP3) for subgroups by erectile dysfunction (ED) characteristics. *p<0.001, †p<0.02, ‡p<0.0002. 
Copyright © 2002. Carson CC, Burnett AL, Levine LA, et al. 2002. The efﬁ  cacy of sildenaﬁ  l citrate (Viagra) in clinical populations: an update. Urology, 60:12-27.
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Despite the proven long-term efficacy of PDE5i, it 
has been suggested that tachyphylaxis to this therapy 
may develop. Long-term treatment with PDE5i and ex-
cessive cGMP accumulation may up-regulate PDE5 (El-
Galley et al 2001). Such hypothesis however, has not 
been proven in the existing clinical trials with chronic 
PDE5i therapy (Behr-Roussel et al 2005; Musicki et al 
2005). Currently, there are no evidence-based data to 
support tachyphylaxis in patients treated with sildenafil 
or any other PDE5i.
Efﬁ  cacy in subpopulations of men 
with ED
The efﬁ  cacy of sildenaﬁ  l in almost every subgroup of pa-
tients with ED is more than established. Response rates in 
elderly men (≥65 years) are comparable with general popula-
tion regardless of age (Wagner et al 2001). No differences in 
response rates were demonstrated in ethnic groups (Young 
et al 2002). In type 1 diabetic patients, 66.6% reported 
improved erections (GAQ) and 63% reported successful 
intercourse attempts compared with 28.6% and 33% by those 
taking placebo, respectively (Stuckey et al 2003). In another 
multicenter, randomized, double-blind, placebo-controlled, 
ﬂ  exible dose-escalation study in diabetic patients, 56% of 
patients reported improved erections and 61% reported at 
least 1 successful intercourse attempt compared with 10% 
and 22% in the placebo group, respectively (Rendell et al 
1999). Diabetic patients are one of the most difﬁ  cult to treat 
subgroups (Behrend et al 2005). In patients after bilateral 
nerve-sparing radical prostatectomy, 76% responded to 
sildenaﬁ  l (deﬁ  ned as successful vaginal intercourse) (Raina 
et al 2004). A favorable response to sildenaﬁ  l in patients 
with ischemic heart disease (GEQ and IIEF Q3 and Q4) 
who were receiving b-blockers and/or angiotensin-convert-
ing enzyme inhibitors and/or calcium channel blockers has 
been observed (Olsson and Persson 2001). Similar results 
presented in patients with hypertension (taking different or 
multiple antihypertensive drugs). High efﬁ  cacy rates pre-
sented in patients on chronic dialysis for renal failure (lower 
doses and longer intervals between treatments are usually 
required) (Chen et al 2001; Mahon et al 2005), after renal 
transplantation (Prieto Castro et al 2001; Sharma et al 2006), 
in spinal cord injuries (Derry et al 2002; Deforge et al 2006) 
and patients with depression (treated with selective serotonin 
reuptake inhibitors [SSRIs] or not) (Seidman et al 2001; 
Nurnberg et al 2002) or patients treated with antipsychotic 
agents (Gopalakrishnan et al 2006). 
Treatment satisfaction and quality 
of life
Both patients and partners report higher levels of 
satisfaction (assessed with the Erectile Dysfunction 
Inventory of Treatment Satisfaction [EDITS] question-
naire) after sildenaﬁ  l treatment relative to placebo (Lewis 
et al 2001). Patients receiving sildenaﬁ  l had signiﬁ  cantly 
higher scores (73.6 ± 3.2) than did those receiving placebo 
(48.4 ± 3.2, p<0.001). The scores on the partner version 
of the EDITS were also signiﬁ  cantly higher among the 
partners of men who received sildenaﬁ  l (63.9 ± 8.1) than 
among the partners of those who received placebo (33.3 ± 
7.5, p<0.001). A high level of treatment satisfaction (65%) 
reported in another clinical practice study (assessed by 
5-item scale) (Jarow et al 1999). Treatment satisfaction 
was correlated with ED severity (41% in severe, 78% 
in moderate, and 100% in mild ED) and etiology (56% 
in neurologic causes, 58% in diabetes, 35% in radical 
prostatectomy, 89% in psychogenic causes, and 86% in 
vasculogenic causes). However, no particular character-
istic predicted absolute failure with sildenaﬁ  l. Sildenaﬁ  l 
also improved all aspects of health-related quality of life 
(assessed by SF-36 or Q13 and Q14 of the IIEF) in general 
ED population or subgroups such as spinal cord injuries 
(Hultling et al 2000; Giuliano et al 2001; Fujisawa et al 
2002). Signiﬁ  cant improvements in self-esteem, conﬁ  -
dence, sexual relationship satisfaction, and overall rela-
tionship satisfaction after treatment of ED with sildenaﬁ  l 
were reported by Althof and colleagues (2006) using the 
self-esteem and relationship questionnaire (SEAR) in a 
cross-cultural double-blind, placebo controlled, ﬂ  exible 
dose study (Althof et al 2006; Cappelleri et al 2006). 
Treatment satisfaction is also maintained through time 
(Figure 3) (Carson et al 2002). 
Data on partner satisfaction support the patients’ satisfaction. 
For the partners of sildenaﬁ  l-treated patients, 74% (younger 
than 65 years) and 67% (65 years or older) were satisﬁ  ed with 
the treatment compared with the partners of placebo-treated 
patients (35% and 22% respectively) (Montorsi and Althof 
2004). Satisfaction deﬁ  ned as EDITS score of greater than 50. 
The quality of partnership as perceived by both the men and their 
female partners is signiﬁ  cantly better in ED patients treated with 
sildenaﬁ  l than in untreated controls (Muller et al 2001). More 
than 90% of partners reported satisfaction with treatment in an 
open prospective study of men with ED receiving sildenaﬁ  l for 
10 weeks (Gil et al 2001). Clinical Interventions in Aging 2006:1(4) 407
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Safety
Adverse events and discontinuation rates
Sildenaﬁ  l has been on the market for more than 8 years. 
Morales and colleagues (1998) provided summarized 
safety until 1998 and Padma-Nathan and colleagues 
(2002) provided long-term safety data (>4 years). The 
most commonly reported treatment-related adverse events 
are headache, facial ﬂ  ushing, dyspepsia, dizziness, nasal 
congestion, abnormal vision, and palpitation (Table 2). 
Other adverse events uncommonly or rarely reported in-
clude back pain, inﬂ  uenza-like syndrome, rash, vomiting, 
diarrhea, cardiac arrhythmia, and hypersensitivity 
reactions. Adverse events are dose related, mild in nature, 
self-limited by continuous use. The drop-out rate due to 
adverse events is similar to placebo (2% for sildenaﬁ  l vs 
2.3% for placebo). Post-marketing case series reported 
higher incidence of adverse events, especially for 
headache (9%–39%), ﬂ  ushing (7%–33%) and abnormal 
vision (5%–11%) (Zippe et al 1998; Jarow et al 1999; 
Marks et al 1999; McMahon et al 2000; Moreira et al 2000; 
Fagelman et al 2001; Guay et al 2001; Martinez-Jabaloyas 
et al 2001; Palumbo et al 2001). Patients may tolerate 
sildenaﬁ  l differently based on existing comorbidities. 
Ischemic heart disease and hypertension are associated 
with higher incidence of adverse events than diabetes 
(3.6%, 2.3%, and 1.9%, respectively) (Padma-Nathan et 
al 2002). Visual disturbances (blurred vision, ﬂ  ashing 
lights, blue haze, and change in color perception) occur 
due to weak inhibition of PDE6 in the retina. They are 
coincident with peak plasma concentrations of sildenaﬁ  l 
and are transient and fully reversible. None persisted 
6 hours after taking sildenaﬁ  l and rarely consist a reason 
to discontinue treatment. 
Cardiovascular safety
Clinical trials and post marketing data of sildenaﬁ  l demon-
strated no increase in myocardial infarction rates in patients 
Figure 3 Patients reporting satisfaction with treatment effect on erections and improvement in ability to engage in sexual activity at end of 1 year, 2 years, and 3 years of 
open-label treatment with sildenaﬁ  l. Copyright © 2002. Carson CC, Burnett AL, Levine LA, et al. 2002. The efﬁ  cacy of sildenaﬁ  l citrate (Viagra) in clinical populations: an 
update. Urology, 60:12-27.
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Table 2 Common adverse events (>1%) of sildenaﬁ  l (from Eu-
ropean Medicine Agency statements on product characteristics)
Adverse event   Sildenaﬁ   l   Placebo 
Headache   10.8%   2.8% 
Flushing    10.9%   1.4% 
Abnormal vision   3.6%   0.4% 
Dyspepsia    3%   0.4% 
Nasal congestion    2.1%   0.3% 
Dizziness   2.9%   1% 
Palpitation   1%   0.2% Clinical Interventions in Aging 2006:1(4) 408
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that received these agents as part of either double  blind, 
placebo controlled trials or open label studies or compared to 
expected rates in aged  matched populations of men (Boshier 
et al 2004). Sildenaﬁ  l does not adversely affect total exercise 
time or time to ischemia during exercise testing in men with 
stable angina. In fact, it may actually improve exercise tests. 
Sildenaﬁ  l does not alter cardiac contractility, cardiac output 
or myocardial oxygen consumption based on evidence re-
viewed to date (Gillies et al 2002; Vlachopoulos et al 2003; 
Kukreja et al 2004; Webster et al 2004).
Several new studies have proven not only the cardio-
vascular safety of sildenaﬁ  l, but have also suggested that 
sildenaﬁ  l may have a cardioprotective role. PDE5A inhibi-
tion by sildenaﬁ  l blunts systolic responses to beta-adrenergic 
stimulation suggesting a possible role in modifying stimu-
lated cardiac function (Borlaug et al 2005). Chronic inhibition 
of cGMP phosphodiesterase 5A by sildenaﬁ  l prevents and 
reverses cardiac hypertrophy (Takimoto et al 2005). Finally, 
sildenaﬁ  l is the only PDE5i that improved arterial oxygena-
tion in patients with pulmonary hypertension (Ghofrani et al 
2004) and it has been recently approved in doses of 20 mg and 
40 mg, taking every 8 h life-long by patients with pulmonary 
hypertension (Galie et al 2005).
Princeton guidelines on use of PDE5i
The Princeton Consensus Recommendations were developed 
to provide instructions to physicians who treat men with 
CVD and ED and answer the most common question: is it 
safe to take PDE5i and engage in sexual activity? (Kostis 
et al 2005). Physicians should consider the cardiovascular 
status of their patients seeking treatment for ED since there 
is a degree of risk associated with sexual activity. Three risk 
categories of CVD were described. Patients in the low risk 
category (controlled hypertension, stable angina, successful 
coronary revascularization, history of uncomplicated myo-
cardial infarction, mild valvular disease, and no symptoms 
with <3 cardiovascular risk factors) can be safely encouraged 
to initiate or resume sexual activity or receive treatment for 
their sexual dysfunction. Patients in the intermediate-risk 
category include those with moderate angina, recent myocar-
dial infarction (<6 weeks), left ventricular dysfunction and/or 
class II congestive heart failure, non-sustained low-risk 
arrhythmias and ≥3 risk factors for coronary artery disease. 
These patients should receive further cardiologic evaluation 
to determine if they can be restratiﬁ  ed into the low- or high-
risk cardiovascular categories. Finally, patients in the high-
risk category should be stabilized for their cardiac condition 
before resuming sexual activity or receiving treatment for 
their sexual dysfunction. It is important to emphasize that the 
use of any form of nitrate with all PDE5i is contraindicated 
because of the increased likelihood of hypotension. 
Sildenaﬁ  l and alpha adrenergic antagonists
Alpha adrenergic antagonists are commonly used drugs in 
patients with BPH-related LUTS. Although the adverse event 
proﬁ  le of sildenaﬁ  l is not worsened by a background of anti-
hypertensive medicines, even when the patient is on multiple 
antihypertensive agents, it appears to have some interaction 
with alpha blockers, which may result in clinically signiﬁ  cant 
orthostatic hypotension under some conditions (Kostis et al 
2005). This is most likely to occur in patients treated with 
doxazosin (a long-acting alpha blocker). Today, alpha block-
ers are no longer considered a contraindication for sildenaﬁ  l, 
but precautions in the use of these drugs are listed. Patients 
who demonstrate hemodynamic instability on alpha-blocker 
therapy alone are at increased risk of symptomatic hypoten-
sion with concomitant use of sildenaﬁ  l. Therefore, patients 
should be stable on alpha-blocker therapy prior to initiating 
sildenaﬁ  l. Treatment with sildenaﬁ  l must be initiated at the 
lowest recommended dose, while it should be taken 3–4 h 
apart from antihypertensive administration.
Sildenaﬁ  l and non-arteritic anterior 
ischemic optic neuropathy (NAION)
Non-arteritic anterior ischemic optic neuropathy (NAION) 
is characterized by acute ischemia of the anterior portion of 
the optic nerve in the absence of provable arteritis, which 
may result in visual ﬁ  eld defect or vision loss. No effective 
treatment is available and prevention is limited to the treat-
ment of risk factors mainly aiming at decreasing the risk of 
a similar event in the fellow eye. Numerous risk factors have 
been reported for NAION, mainly cardiovascular risk factors, 
including hypertension, diabetes, and hypercholesterolemia. 
Lastly, the potential relationship between non-arteritic an-
terior ischemic optic neuropathy (NAION) and PDE5i use 
has raised important questions and a strong reaction not only 
among regulatory agencies, but also within the scientiﬁ  c 
community and mass media as well.
There are 16 NAION case reports published in association 
with sildenaﬁ  l. A few of the cases associated with sildenaﬁ  l 
use experienced temporary partial visual loss that became 
a ﬁ  xed visual loss upon rechallenge (Hatzichristou 2005). 
As sildenaﬁ  l has been used by more than 30 million men 
worldwide and the incidence of NAION has been reported Clinical Interventions in Aging 2006:1(4) 409
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as 2.3 per 100 000 persons, we would expect far more than 
the reported 16 cases associated with the use of sildenaﬁ  l. 
According to the European Medicines Agency (EMEA) la-
beling however, patients taking or considering taking PDE5i 
should inform their healthcare professionals if they have 
ever had severe loss of vision, which might reﬂ  ect a prior 
episode of NAION, as such patients are at an increased risk 
of developing NAION again and they should be referred to 
the ophthalmologist (Wespes et al 2006).
Management strategy for 
treatment failures
Deﬁ  nition of treatment failure 
to sildenaﬁ  l
Although the term ‘treatment failure’ to oral drugs is 
widely used, there is no precise deﬁ  nition of what exactly 
means. Treatment failure may be due to medication, 
clinician and patient issues (Table 3). Based on these issues 
a deﬁ  nition of a non-responder to oral pharmacotherapy is 
proposed: “an inadequate erectile response after at least 
4 attempts of the highest tolerated drug dose in accordance 
with manufacturer’s guidelines with respect to timing 
relative to meals, alcohol ingestion, use of concomitant 
medications, and adequate sexual stimulation/arousal” 
(Carson et al 2004).
Besides these reasons for inappropriate intake of silde-
naﬁ  l, one of the most common causes of discontinuation of 
a drug that is considered as treatment failure is the lack of 
follow-up of the patients. Erectile dysfunction is a chronic 
disease. Follow-up visits are essential to improve physician–
patient communication, solve treatment problems that may 
have occurred, identify any change in potency status or new 
medical conditions and offer continuing education to patients 
and their partners. These essential aspects in managing ED 
patients can be easily remembered by the acronym, FAST 
(Follow-up of patients, Adjustment of time of administration, 
Sexual stimulation, and Titration to the maximum tolerated 
dose) (Hatzichristou 2002). 
Identifying truly treatment failures
In order to identify truly treatment failures, the physician need 
to address all the medication, clinician and patient/partner 
issues that were previously presented. The probability of a 
misdiagnosis due to incomplete basic diagnostic evaluation 
from a non-expert physician must also be investigated (Hat-
zichristou et al 2002). These are patients with hypogonadism 
or hyperprolactinemia who need speciﬁ  c hormonal manipu-
lation in order to cure erectile dysfunction (Greenstein et al 
2005), patients with Peyronie’s disease who need treatment 
for penile curvature or pain during intercourse, and patients 
who do not have erectile dysfunction but they experience 
ejaculatory dysfunction or sensory disturbances.
After proper counseling and instructions were given, the 
patient is encouraged for a re-trial of the oral drug for at least 4 
attempts for intercourse with the new instructions on adminis-
tration, as a recent study revealed inappropriate intake of silde-
naﬁ  l in 56% of treatment failures (Hatzichristou et al 2005). 
After adequate instructions on the proper use of sildenaﬁ  l, one 
third of the initially non-responders to sildenaﬁ  l converted to 
responders. The most easily reversible factor for treatment 
failure was the administration of sildenaﬁ  l just before initia-
tion of sexual activity followed by absence of sexual desire on 
sildenaﬁ  l uptake and use of the drug with a full stomach. In 
this study, 12% of sildenaﬁ  l failures were not aware that sexual 
stimulation was mandatory to achieve an erection, but 50% of 
them converted to responders when they were explained that 
sildenaﬁ  l does not possess aphrodisiac properties. Addition-
ally, 63.6% of the patients who initially used the drug just 
before the initiation of sexual intercourse and 34.4% of those 
who took sildenaﬁ  l with a full stomach responded to sildenaﬁ  l 
with appropriate timing of administration.
Similar results were presented by other studies. Incorrect 
administration accounted for 81% of sildenafil failures 
Table 3 Factors leading to an inadequate trial of oral pharmacotherapy
Medication issues   Clinician  issues   Patient  issues 
Published efﬁ  cacy rates      Inadequate   Unrealistic expectations 
 administration 
 instructions   
Special populations reﬂ  ect   Inappropriate dosing    Lack of persistence   
variable responses 
(difﬁ  cult-to-treat subgroups)    
Side-effects   Misdiagnosis   Fear 
    Lack of follow up   Unaddressed  psychological  issues 
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referred by primary care physicians (Atiemo et al 2003). 
Reasons included administration after heavy meals, lack of 
sexual stimulation, short timing to intercourse, and too few 
attempts for intercourse. The authors were able to salvage 
41.5% of nonresponders after reeducation as measured by 
the General Assessment Question (GAG) and Sexual Health 
Inventory for Men (SHIM) scores. Gruenwald and colleagues 
(2006) showed that counseling and dose adjustment were 
directly inﬂ  uential in achieving an excellent response to 
a second trial of sildenaﬁ  l in patients with ED who had 
previously failed treatment with the drug, and obviated their 
needing to seek more invasive measures. In this study, 38% 
of the included patients did not receive any explanations or 
counseling whatsoever from the prescribing physician. After 
proper instruction, erectile function domain scores increased 
signiﬁ  cantly and overall 23.6% of the patients had a normal 
IIEF EF domain score (≥26) at the end of the study. 
A patient is considered as truly non-responder, if re-
trial of oral therapy after proper counseling and instruction 
administration fails. 
Treatment of truly non-responders
Today, it is widely accepted that treatment approach follows 
a step-wise model. A patient failing oral pharmacotherapy 
has to go on second line therapies that include intracavernosal 
injections and combination treatments. If he further fails 
second line therapies, the only option is a third line therapy 
that is implantation of a penile prosthesis.
Preliminary data show that higher doses of sildenaﬁ  l (up 
to 200 mg) may salvage some patients who where sildenaﬁ  l 
nonresponders. McMahon (2002) concluded that sildenaﬁ  l 
at doses of up to 200 mg is an effective salvage therapy for 
24.1% of previous sildenaﬁ  l non-responders but is limited by 
a signiﬁ  cantly higher incidence of adverse effects and a 31% 
treatment discontinuation rate. McMahon and colleagues 
(1999) also used sildenaﬁ  l as salvage therapy in intracaver-
nosal injection non-responders (alprostadil or tri-mix). They 
were able to salvage 31% of patients with combination of 
sildenaﬁ  l with intracavernosal injection of tri-mix. However, 
combination therapy was associated with a 33% incidence 
of adverse effects, including a 20% incidence of dizziness 
side effects (McMahon et al 1999). Finally, preliminary data 
suggest a possible role for combination treatment with caber-
goline (Safarinejad 2006) or statins (Herrmann et al 2006; 
Osborne 2006) in non-responders to sildenaﬁ  l alone.
Intracavernosal injections remain an excellent treatment 
option with proven efﬁ  cacy and safety over time. Baniel 
and colleagues (2001) treated sildenaﬁ  l non-responders 
after radical prostatectomy with intracavernosal injections 
of vasoactive drugs with 85% success rate. Shabsigh and 
colleagues (2000) were able to salvage sildenaﬁ  l non re-
sponders with intracavernosal injections of alprostadil. 
More than 85% improvement in Q3 and Q4 of the IIEF 
was recorded (Shabsigh et al 2000). The tri-mix combina-
tion (papaverine, phentolamine, alprostadil) is certainly the 
more efﬁ  cacious drug treatment for erectile dysfunction and 
can be used in severe cases of erectile dysfunction when 
intravernous alprostadil fails or it is not preferable due to 
side effects.
The patient should be given every opportunity to choose 
among options, and to determine which ﬁ  ts best to his special 
needs and expectations. The clinician should also provide a 
supportive environment for shared decision-making. This 
management strategy must be supplemented by a careful fol-
low-up in order to identify changes in patients’ expectations, 
possible side effects that may need treatment optimization.
Use of sildenaﬁ  l in aging men
The normal aging process and age related risk factor accu-
mulation contribute to the increased prevalence of erectile 
dysfunction in the elderly. Systemic changes and alterations 
in the structure and function of the penis in elderly men 
include hormonal changes (mainly testosterone decrease 
and increase in sex hormone binding globulin that resulting 
decreased bioavailability of testosterone) (Margolese 2000), 
decrease in elastic ﬁ  bers and increase in collagen ﬁ  bers 
in the tunica albuginea (Akkus et al 1997) and molecular 
changes (decrease in nitric oxide synthase) (Andrew and 
Mayer 1999).
Older men (aged ≥65 years) have higher plasma concen-
trations of sildenaﬁ  l compared with younger men (18–45 
years), with mean maximum concentration (Cmax) 70% 
greater in older men and mean area under the curve (AUC) 
84% higher compared with the younger age group. Due to 
age-differences in plasma protein binding, the correspond-
ing increase in free sildenaﬁ  l plasma concentration was 
approximately 40%. However, no differences in the safety 
of any dose of sildenaﬁ  l were observed in older patients 
compared with younger men. Therefore, dosage adjustments 
are not required in elderly patients (Seftel 2003). Sildenaﬁ  l 
signiﬁ  cantly improves erectile function in elderly patients 
with erectile dysfunction of broad etiology although efﬁ  cacy 
rates may be lower compared with younger men due to the 
normal aging process and age related risk factor accumulation 
mentioned before (Rendell et al 1999; Wagner et al 2001; 
Carson et al 2002).Clinical Interventions in Aging 2006:1(4) 411
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The need for a patient-centered 
care model in sexual medicine
Erectile dysfunction is a self-reported condition by the 
patients and the results of different treatment modalities 
are also self-evaluated (Hatzimouratidis and Hatzichristou 
2005). Recent data on ED treatment outcome have shown 
that many patients discontinue treatment, despite the avail-
ability of efﬁ  cacious pharmacotherapies, because doctors 
fail to inform patients properly and to ensure continuity in 
care, as well as to be routinely involved in asking patients 
about their needs and expectations (Mulhall et al 1999; Hat-
zichristou et al 2005). Althof (2002) described several causes 
that may contribute, including the length of time the couple 
were asexual before seeking treatment, the man’s approach to 
resuming a sexual life with his partner, the female partner’s 
physical and emotional readiness to resume lovemaking, the 
meaning for each partner of using a medical intervention to 
enable intercourse and the quality of the nonsexual aspects 
of the relationship. It becomes apparent that patients’ needs 
and expectations vary widely and the treatment approach 
should always be individualized according to their prefer-
ence for information and involvement in the decision-making 
process. Patient satisfaction is a complex issue that depends 
not only on therapeutic outcomes in terms of efﬁ  cacy and 
adverse events or complications but also on expectations 
from treatment and relationship dynamics. 
Such observations augment the need for the development 
of care model in sexual medicine, as it happens with every 
other chronic condition, such as diabetes mellitus and CVD. 
In addition, it becomes clear that we are running to the era 
where personalized medicine will replace traditional schema; 
diagnosis is integrated with therapy for selection of the 
treatment as well for monitoring the outcome. Development 
and adaptation of a patient-centered care model in sexual 
medicine will increase efﬁ  cacy and safety of currently and 
future treatments, as well as patients’ adherence, with certain 
beneﬁ  ts not only for our patients, but also for the healthcare 
systems, especially in terms of cost-effectiveness.
Future perspectives
Prophylactic use of sildenaﬁ  l
Early use of vasoactive agents has been shown to rehabili-
tate erectile function after nerve sparing radical retropubic 
prostatectomy (RRP) (Montorsi et al 2004). 
In a double-blind , placebo-controlled study, sildenaﬁ  l 
(50 mg–100 mg) taken every night for 9 months, starting 
1 month after nerve sparing radical prostatectomy was 
associated with recovery of spontaneous erections in 27% 
of patients compared with 4% of patients taking placebo 
(Padma-Nathan et al 2003). Schwartz and colleagues (2004), 
in a study of 40 potent volunteers with prostate cancer who 
underwent RRP, showed that sildenaﬁ  l administration every 
other night for 6 months, substantially increases corporal 
smooth muscle content. The most promising prophylactic 
role of sildenaﬁ  l is clearly the preservation of the smooth 
muscle of the corpora cavernosa.
Sildenaﬁ  l in patients with lower urinary 
tract symptoms (LUTS)
Lower urinary tract symptoms (LUTS) are independent risk 
factors for sexual dysfunction in older men (Rosen et al 
2003). A possible role for PDE5i in the treatment of LUTS 
has been presented (McVary 2005). Sairam and colleagues 
(2002) showed that ED treatment with sildenaﬁ  l improved 
both sexual function scores (based on IIEF) and LUTS and 
urinary scores correlated strongly with sexual function scores 
at 3 months. Mulhall and colleagues (2006), in a group of ED 
patients treated with sildenaﬁ  l, similarly noticed that 60% 
of men improved their IPSS score, and 35% had at least a 
4-point improvement in their score. If ongoing clinical re-
search proves these preliminary data, it will open the avenue 
for innovative therapeutic approaches. 
Sildenaﬁ  l in patients with premature 
ejaculation
PDE5i have been suggested to be beneﬁ  cial for patients 
with premature ejaculation, possibly due to a peripheral 
inhibition of contractile response of vas deferens, seminal 
vesicles, prostate, and urethra as well as a reduced central 
sympathetic output through a prolonged NO effect (Abdel-
Hamid 2004). Combination of sildenaﬁ  l with paroxetine 
prolongs signiﬁ  cantly intravaginal ejaculation latency time 
(IELT) and is associated with better intercourse satisfaction 
compared with paroxetine alone (Salonia et al 2002). In a 
group of nonresponders to other treatments, sildenaﬁ  l com-
bined with paroxetine and psychological -behavioral coun-
seling alleviated premature ejaculation (Chen et al 2003). 
On the contrary, sildenaﬁ  l was not superior to placebo or 
combination treatment with topical lidocain/prilocain cream. 
Further placebo-controlled, well designed studies are needed 
to determine whether there is any role for sildenaﬁ  l in the 
treatment of premature ejaculation.
Conclusions
Sildenaﬁ  l is a highly effective treatment associated with a 
good safety and tolerability proﬁ  le in men with ED. It is Clinical Interventions in Aging 2006:1(4) 412
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also effective in several subpopulations although efﬁ  cacy is 
lower in the so called difﬁ  cult-to-treat subpopulations such as 
patients with diabetes mellitus or after radical prostatectomy, 
including men in older age groups. Sildenaﬁ  l signiﬁ  cantly 
improves satisfaction and quality of life for both patients 
and partners. Furthermore, new data from basic and clinical 
research suggest a possible role in the future for several other 
chronic conditions. 
References 
Abdel-Hamid IA. 2004. Phosphodiesterase 5 inhibitors in rapid ejaculation: 
potential use and possible mechanisms of action. Drugs, 64:13-26.
Akkus E, Carrier S, Baba K, et al. 1997. Structural alterations in the tunica 
albuginea of the penis: impact of Peyronie’s disease, ageing and im-
potence. Br J Urol, 79:47-53.
Althof SE. 2002. When an erection alone is not enough: biopsychosocial 
obstacles to lovemaking. Int J Impot Res, 14(Suppl 1):S99-104.
Althof SE, O’Leary MP, Cappelleri JC, et al. 2006. Sildenaﬁ  l citrate im-
proves self-esteem, conﬁ  dence, and relationships in men with erectile 
dysfunction: Results from an international, multi-center, double-blind, 
placebo-controlled trial. J Sex Med, 3:521-9.
Andrew PJ, Mayer B. 1999. Enzymatic function of nitric oxide synthases. 
Cardiovasc Res, 43:521-31.
Atan A, Basar MM, Tuncel A, et al. 2006. Comparison of efﬁ  cacy of sildena-
ﬁ  l-only, sildenaﬁ  l plus topical EMLA cream, and topical EMLA-cream-
only in treatment of premature ejaculation. Urology, 67:388-91.
Atiemo HO, Szostak MJ, Sklar GN. 2003. Salvage of sildenaﬁ  l failures 
referred from primary care physicians. J Urol, 170:2356-8.
Aytac IA, McKinlay JB, Krane RJ. 1999. The likely worldwide increase in 
erectile dysfunction between 1995 and 2025 and some possible policy 
consequences. BJU Int, 84:50-6.
Ballard SA, Gingell CJ, Tang K, et al. 1998. Effects of sildenaﬁ  l on the 
relaxation of human corpus cavernosum tissue in vitro and on the 
activities of cyclic nucleotide phosphodiesterase isozymes. J Urol, 
159:2164-71.
Baniel J, Israilov S, Segenreich E, et al. 2001. Comparative evaluation of 
treatments for erectile dysfunction in patients with prostate cancer after 
radical retropubic prostatectomy. BJU Int, 88:58-62.
Behr-Roussel D, Gorny D, Mevel K, et al. 2005. Chronic sildenaﬁ  l improves 
erectile function and endothelium-dependent cavernosal relaxations in 
rats: lack of tachyphylaxis. Eur Urol, 47:87-91.
Behrend L, Vibe-Petersen J, Perrild H. 2005. Sildenaﬁ  l in the treatment of 
erectile dysfunction in men with diabetes: demand, efﬁ  cacy and patient 
satisfaction. Int J Impot Res, 17:264-9.
Boolell M, Allen MJ, Ballard SA, et al. 1996. Sildenaﬁ  l: an orally active type 
5 cyclic GMP-speciﬁ  c phosphodiesterase inhibitor for the treatment of 
penile erectile dysfunction. Int J Impot Res, 8:47-52.
Borlaug BA, Melenovsky V, Marhin T, et al. 2005. Sildenaﬁ  l inhibits 
beta-adrenergic-stimulated cardiac contractility in humans. Circula-
tion, 112:2642-9.
Boshier A, Wilton LV and Shakir SA 2004. Evaluation of the safety of 
sildenaﬁ  l for male erectile dysfunction: experience gained in general 
practice use in England in 1999. BJU Int, 93:796-801.
Braun M, Wassmer G, Klotz T, et al. 2000. Epidemiology of erectile 
dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res, 
12:305-11.
Cappelleri JC, Bell SS, Althof SE, et al. 2006. Comparison between sildena-
ﬁ  l-treated subjects with erectile dysfunction and control subjects on the 
Self-Esteem And Relationship questionnaire. J Sex Med, 3:274-82.
Carson C, Giuliano F, Goldstein I, et al. 2004. The ‘effectiveness’ scale—
therapeutic outcome of pharmacologic therapies for ED: an international 
consensus panel report. Int J Impot Res, 16:207-13.
Carson CC, Burnett AL, Levine LA, et al. 2002. The efﬁ  cacy of sildenaﬁ  l ci-
trate (Viagra) in clinical populations: an update. Urology, 60:12-27.
Chen J, Mabjeesh NJ, Greenstein A, et al. 2001. Clinical efﬁ  cacy of sildenaﬁ  l 
in patients on chronic dialysis. J Urol, 165:819-21.
Chen J, Mabjeesh NJ, Matzkin H, et al. 2003. Efﬁ  cacy of sildenaﬁ  l as ad-
juvant therapy to selective serotonin reuptake inhibitor in alleviating 
premature ejaculation. Urology, 61:197-200.
Deforge D, Blackmer J, Garritty C, et al. 2006. Male erectile dysfunc-
tion following spinal cord injury: a systematic review. Spinal Cord, 
44:465-73
Derry F, Hultling C, Seftel AD, et al. 2002. Efﬁ  cacy and safety of sildenaﬁ  l 
citrate (Viagra) in men with erectile dysfunction and spinal cord injury: 
a review. Urology, 60:49-57.
Desouza C, Parulkar A, Lumpkin D, et al. 2002. Acute and prolonged ef-
fects of sildenaﬁ  l on brachial artery ﬂ  ow-mediated dilatation in type 2 
diabetes. Diabetes Care, 25:1336-9.
El-Galley R, Rutland H, Talic R, et al. 2001. Long-term efﬁ  cacy of sildenaﬁ  l 
and tachyphylaxis effect. J Urol, 166:927-31.
Fagelman E, Fagelman A, Shabsigh R. 2001. Efﬁ  cacy, safety, and use of 
sildenaﬁ  l in urologic practice. Urology, 57:1141-4.
Feldman HA, Goldstein I, Hatzichristou DG, et al. 1994. Impotence and its 
medical and psychosocial correlates: results of the Massachusetts Male 
Aging Study. J Urol, 151:54-61.
Fujisawa M, Sawada K, Okada H, et al. 2002. Evaluation of health-related 
quality of life in patients treated for erectile dysfunction with viagra 
(sildenaﬁ  l citrate) using SF-36 score. Arch Androl, 48:15-21.
Galie N, Ghofrani HA, Torbicki A, et al. 2005. Sildenaﬁ  l citrate therapy for 
pulmonary arterial hypertension. N Engl J Med, 353:2148-57.
Gbekor E, Bethell S, Fawcett L, et al. 2002. Selectivity of sildenaﬁ  l and 
other phoshodiesterase type 5 (PDE5) inhibitors against all human 
phoshodiesterase families. Eur Urol Suppl, 1:63.
Gemalmaz H, Waldeck K, Chapman TN, et al. 2001. In vivo and in vitro 
investigation of the effects of sildenaﬁ  l on rat cavernous smooth muscle. 
J Urol, 165:1010-14.
Ghofrani HA, Voswinckel R, Reichenberger F, et al. 2004. Differences in 
hemodynamic and oxygenation responses to three different phosphodi-
esterase-5 inhibitors in patients with pulmonary arterial hypertension: a 
randomized prospective study. J Am Coll Cardiol, 44:1488-96.
Gil A, Martinez E, Oyaguez I, et al. 2001. Erectile dysfunction in a primary 
care setting: results of an observational, no-control-group, prospective 
study with sildenaﬁ  l under routine conditions of use. Int J Impot Res, 
13:338-47.
Gillies HC, Roblin D, Jackson G. 2002. Coronary and systemic hemody-
namic effects of sildenaﬁ  l citrate: from basic science to clinical studies 
in patients with cardiovascular disease. Int J Cardiol, 86:131-41.
Giuliano F, Pena BM, Mishra A, et al. 2001. Efﬁ  cacy results and quality-
of-life measures in men receiving sildenaﬁ  l citrate for the treatment of 
erectile dysfunction. Qual Life Res, 10:359-69.
Goldstein I, Lue TF, Padma-Nathan H, et al. 1998. Oral sildenaﬁ  l in the 
treatment of erectile dysfunction. Sildenaﬁ  l Study Group. N Engl J 
Med, 338:1397-404.
Gopalakrishnan R, Jacob KS, Kuruvilla A, et al. 2006. Sildenaﬁ  l in the 
treatment of antipsychotic-induced erectile dysfunction: a randomized, 
double-blind, placebo-controlled, ﬂ  exible-dose, two-way crossover 
trial. Am J Psychiatry, 163:494-9.
Gori T, Sicuro S, Dragoni S, et al. 2005. Sildenaﬁ  l prevents endothelial 
dysfunction induced by ischemia and reperfusion via opening of ad-
enosine triphosphate-sensitive potassium channels: a human in vivo 
study. Circulation, 111:742-6.
Greenstein A, Mabjeesh NJ, Sofer M, et al. 2005. Does sildenaﬁ  l combined with 
testosterone gel improve erectile dysfunction in hypogonadal men in whom 
testosterone supplement therapy alone failed? J Urol, 173:530-2.
Gruenwald I, Shenfeld O, Chen J, et al. 2006. Positive effect of counseling 
and dose adjustment in patients with erectile dysfunction who failed 
treatment with sildenaﬁ  l. Eur Urol, 50:134-40.Clinical Interventions in Aging 2006:1(4) 413
Sildenaﬁ  l in the treatment of erectile dysfunction
Guay AT, Perez JB, Jacobson J, et al. 2001. Efﬁ  cacy and safety of sildenaﬁ  l 
citrate for treatment of erectile dysfunction in a population with associ-
ated organic risk factors. J Androl, 22:793-7.
Halcox JP, Nour KR, Zalos G, et al. 2002. The effect of sildenaﬁ  l on human 
vascular function, platelet activation, and myocardial ischemia. J Am 
Coll Cardiol, 40:1232-40.
Hatzichristou D. 2005. Phosphodiesterase 5 inhibitors and nonarteritic an-
terior ischemic optic neuropathy (NAION): coincidence or causality? 
J Sex Med, 2:751-8.
Hatzichristou D, Hatzimouratidis K, Bekas M, et al. 2002. Diagnostic 
steps in the evaluation of patients with erectile dysfunction. J Urol, 
168:615-20.
Hatzichristou D, Moysidis K, Apostolidis A, et al. 2005. Sildenaﬁ  l failures 
may be due to inadequate patient instructions and follow-up: a study 
on 100 non-responders. Eur Urol, 47:518-22.
Hatzichristou DG. 2002. Sildenaﬁ  l citrate: lessons learned from 3 years of 
clinical experience. Int J Impot Res, 14(Suppl 1):S43-52.
Hatzichristou DG, Pescatori ES. 2001. Current treatments and emerging 
therapeutic approaches in male erectile dysfunction. BJU Int, 88(Suppl 
3):11-17.
Hatzimouratidis K, Hatzichristou DG. 2005. A comparative review of the 
options for treatment of erectile dysfunction: which treatment for which 
patient? Drugs, 65:1621-50.
Herrmann HC, Levine LA, Macaluso J, Jr., et al. 2006. Can atorvastatin 
improve the response to sildenaﬁ  l in men with erectile dysfunction not 
initially responsive to sildenaﬁ  l? Hypothesis and pilot trial results. J 
Sex Med, 3:303-8.
Hirata K, Adji A, Vlachopoulos C, et al. 2005. Effect of sildenaﬁ  l on cardiac 
performance in patients with heart failure. Am J Cardiol, 96:1436-40.
Hultling C, Giuliano F, Quirk F, et al. 2000. Quality of life in patients with 
spinal cord injury receiving Viagra (sildenaﬁ  l citrate) for the treatment 
of erectile dysfunction. Spinal Cord, 38:363-70.
Jarow JP, Burnett AL, Geringer AM. 1999. Clinical efﬁ  cacy of sildenaﬁ  l 
citrate based on etiology and response to prior treatment. J Urol, 
162:722-5.
Katz SD, Balidemaj K, Homma S, et al. 2000. Acute type 5 phosphodieste-
rase inhibition with sildenaﬁ  l enhances ﬂ  ow-mediated vasodilation in 
patients with chronic heart failure. J Am Coll Cardiol, 36:845-51.
Kostis JB, Jackson G, Rosen R, et al. 2005. Sexual dysfunction and cardiac 
risk (the Second Princeton Consensus Conference). Am J Cardiol, 
96:313-21.
Kukreja RC, Ockaili R, Salloum F, et al. 2004. Cardioprotection with 
phosphodiesterase-5 inhibition—a novel preconditioning strategy. J 
Mol Cell Cardiol, 36:165-73.
Langtry HD, Markham A. 1999. Sildenaﬁ  l: a review of its use in erectile 
dysfunction. Drugs, 57:967-89.
Lewis R, Bennett CJ, Borkon WD, et al. 2001. Patient and partner satis-
faction with Viagra (sildenaﬁ  l citrate) treatment as determined by the 
Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. 
Urology, 57:960-5.
Mahon A, Sidhu PS, Muir G, et al. 2005. The efﬁ  cacy of sildenaﬁ  l for the 
treatment of erectile dysfunction in male peritoneal dialysis patients. 
Am J Kidney Dis, 45:381-7.
Margolese HC. 2000. The male menopause and mood: testosterone decline 
and depression in the aging male – is there a link? J Geriatr Psychiatry 
Neurol, 13:93-101.
Marks LS, Duda C, Dorey FJ, et al. 1999. Treatment of erectile dysfunction 
with sildenaﬁ  l. Urology, 53:19-24.
Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. 2001. Preva-
lence and independent risk factors for erectile dysfunction in Spain: 
results of the Epidemiologia de la Disfuncion Erectil Masculina Study. 
J Urol, 166:569-74.
Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R, et al. 2001. 
Prognostic factors for response to sildenaﬁ  l in patients with erectile 
dysfunction. Eur Urol, 40:641-6.
McMahon CG. 2002. High dose sildenaﬁ  l citrate as a salvage therapy for 
severe erectile dysfunction. Int J Impot Res, 14:533-8.
McMahon CG, Samali R, Johnson H. 1999. Treatment of intracorporeal 
injection nonresponse with sildenaﬁ  l alone or in combination with triple 
agent intracorporeal injection therapy. J Urol, 162:1992-7.
McMahon CG, Samali R, Johnson H. 2000. Efﬁ  cacy, safety and patient 
acceptance of sildenaﬁ  l citrate as treatment for erectile dysfunction. 
J Urol, 164:1192-6.
McVary KT. 2005. Erectile dysfunction and lower urinary tract symptoms 
secondary to BPH. Eur Urol, 47:838-45.
Moncada I, Jara J, Subira D, et al. 2004. Efﬁ  cacy of sildenaﬁ  l citrate at 12 
hours after dosing: re-exploring the therapeutic window. Eur Urol, 
46:357-60.
Montorsi F, Althof SE. 2004. Partner responses to sildenaﬁ  l citrate (Viagra) 
treatment of erectile dysfunction. Urology, 63:762-7.
Montorsi F, Briganti A, Salonia A, et al. 2004. Current and future strategies 
for preventing and managing erectile dysfunction following radical 
prostatectomy. Eur Urol, 45:123-33.
Montorsi F, Briganti A, Salonia A, et al. 2003. Erectile dysfunction preva-
lence, time of onset and association with risk factors in 300 consecu-
tive patients with acute chest pain and angiographically documented 
coronary artery disease. Eur Urol, 44:360-4.
Morales A, Gingell C, Collins M, et al. 1998. Clinical safety of oral silde-
naﬁ  l citrate (VIAGRA) in the treatment of erectile dysfunction. Int J 
Impot Res, 10:69-73.
Moreira SG, Jr., Brannigan RE, Spitz A, et al. 2000. Side-effect proﬁ  le of 
sildenaﬁ  l citrate (Viagra) in clinical practice. Urology, 56:474-6.
Mulhall JP, Guhring P, Parker M, et al. 2006. Assessment of the impact of 
sildenaﬁ  l citrate on lower urinary tract symptoms in men with erectile 
dysfunction. J Sex Med, 3:662-7.
Mulhall JP, Jahoda AE, Cairney M, et al. 1999. The causes of patient 
dropout from penile self-injection therapy for impotence. J Urol, 
162:1291-4.
Muller MJ, Ruof J, Graf-Morgenstern M, et al. 2001. Quality of partner-
ship in patients with erectile dysfunction after sildenaﬁ  l treatment. 
Pharmacopsychiatry, 34:91-5.
Musicki B, Champion HC, Becker RE, et al. 2005. In vivo analysis of chronic 
phosphodiesterase-5 inhibition with sildenaﬁ  l in penile erectile tissues: 
no tachyphylaxis effect. J Urol, 174:1493-6.
Nurnberg HG, Seidman SN, Gelenberg AJ, et al. 2002. Depression, anti-
depressant therapies, and erectile dysfunction: clinical trials of silde-
naﬁ  l citrate (Viagra) in treated and untreated patients with depression. 
Urology, 60:58-66.
Olsson AM, Persson CA. 2001. Efﬁ  cacy and safety of sildenaﬁ  l citrate for 
the treatment of erectile dysfunction in men with cardiovascular disease. 
Int J Clin Pract, 55:171-6.
Osborne T. 2006. Statin treatment improves erectile dysfunction in sildenaﬁ  l 
nonresponders. Nat Clin Pract Urol, 3:239-40.
Padma-Nathan H, Eardley I, Kloner RA, et al. 2002. A 4-year update on the 
safety of sildenaﬁ  l citrate (Viagra). Urology, 60:67-90.
Padma-Nathan H, Mc Cullough AR, Giulano F, et al. 2003. Postoperative 
nightly administration of sildenaﬁ  l citrate signiﬁ  cantly improves the 
return of normal spontaneous erectile function after bilateral nerve-
sparing radical prostatectomy. J Urol, 169(Suppl):375.
Padma-Nathan H, Stecher VJ, Sweeney M, et al. 2003. Minimal time to 
successful intercourse after sildenaﬁ  l citrate: results of a randomized, 
double-blind, placebo-controlled trial. Urology, 62:400-3.
Palumbo F, Bettocchi C, Selvaggi FP, et al. 2001. Sildenaﬁ  l: efﬁ  cacy and 
safety in daily clinical experience. Eur Urol, 40:176-80.
Papaharitou S, Athanasiadis L, Nakopoulou E, et al. 2006. Erectile dysfunc-
tion and premature ejaculation are the most frequently self-reported 
sexual concerns: proﬁ  les of 9,536 men calling a helpline. Eur Urol, 
49:557-63.
Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC, et al. 2001. 
Treatment with sildenaﬁ  l citrate in renal transplant patients with erectile 
dysfunction. BJU Int, 88:241-3.Clinical Interventions in Aging 2006:1(4) 414
Hatzimouratidis
Raina R, Lakin MM, Agarwal A, et al. 2004. Long-term intracavernous 
therapy responders can potentially switch to sildenaﬁ  l citrate after 
radical prostatectomy. Urology, 63:532-7.
Rendell MS, Rajfer J, Wicker PA, et al. 1999. Sildenaﬁ  l for treatment of 
erectile dysfunction in men with diabetes: a randomized controlled trial. 
Sildenaﬁ  l Diabetes Study Group. JAMA, 281:421-6.
Rosen R, Altwein J, Boyle P, et al. 2003. Lower urinary tract symptoms and 
male sexual dysfunction: the multinational survey of the aging male 
(MSAM-7). Eur Urol, 44:637-49.
Safarinejad MR. 2006. Salvage of sildenaﬁ  l failures with cabergoline: a 
randomized, double-blind, placebo-controlled study. Int J Impot Res, 
in press.
Sairam K, Kulinskaya E, McNicholas TA, et al. 2002. Sildenaﬁ  l inﬂ  uences 
lower urinary tract symptoms. BJU Int, 90:836-9.
Salonia A, Maga T, Colombo R, et al. 2002. A prospective study compar-
ing paroxetine alone versus paroxetine plus sildenaﬁ  l in patients with 
premature ejaculation. J Urol, 168:2486-9.
Schwartz EJ, Wong P, Graydon RJ. 2004. Sildenaﬁ  l preserves intracor-
poreal smooth muscle after radical retropubic prostatectomy. J Urol, 
171:771-4.
Seftel AD. 2003. Erectile dysfunction in the elderly: epidemiology, etiology 
and approaches to treatment. J Urol, 169:1999-2007.
Seidman SN, Roose SP, Menza MA, et al. 2001. Treatment of erectile 
dysfunction in men with depressive symptoms: results of a placebo-
controlled trial with sildenaﬁ  l citrate. Am J Psychiatry, 158:1623-30.
Shabsigh R, Padma-Nathan H, Gittleman M, et al. 2000. Intracavernous 
alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients 
with erectile dysfunction after failing sildenaﬁ  l (Viagra). Urology, 
55:477-80.
Sharma RK, Prasad N, Gupta A, et al. 2006. Treatment of erectile dysfunc-
tion with sildenaﬁ  l citrate in renal allograft recipients: a randomized, 
double-blind, placebo-controlled, crossover trial. Am J Kidney Dis, 
48:128-33.
Steers W, Guay AT, Leriche A, et al. 2001. Assessment of the efﬁ  cacy and 
safety of Viagra (sildenaﬁ  l citrate) in men with erectile dysfunction 
during long-term treatment. Int J Impot Res, 13:261-7.
Stief CG, Uckert S, Becker AJ, et al. 1998. The effect of the speciﬁ  c phos-
phodiesterase (PDE) inhibitors on human and rabbit cavernous tissue 
in vitro and in vivo. J Urol, 159:1390-3.
Stuckey BG, Jadzinsky MN, Murphy LJ, et al. 2003. Sildenaﬁ  l citrate for 
treatment of erectile dysfunction in men with type 1 diabetes: results 
of a randomized controlled trial. Diabetes Care, 26:279-84.
Takimoto E, Champion HC, Li M, et al. 2005. Chronic inhibition of cyclic 
GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. 
Nat Med, 11:214-22.
Vlachopoulos C, Hirata K and O’Rourke MF 2003. Effect of sildenaﬁ  l on 
arterial stiffness and wave reﬂ  ection. Vasc Med, 8:243-8.
Vlachopoulos C, Tsekoura D, Alexopoulos N, et al. 2004. Type 5 phos-
phodiesterase inhibition by sildenaﬁ  l abrogates acute smoking-induced 
endothelial dysfunction. Am J Hypertens, 17:1040-4.
Wagner G, Montorsi F, Auerbach S, et al. 2001. Sildenaﬁ  l citrate (VIAGRA) 
improves erectile function in elderly patients with erectile dysfunction: 
a subgroup analysis. J Gerontol A Biol Sci Med Sci, 56:M113-19.
Webster LJ, Michelakis ED, Davis T, et al. 2004. Use of sildenaﬁ  l for safe 
improvement of erectile function and quality of life in men with New 
York Heart Association classes II and III congestive heart failure: a 
prospective, placebo-controlled, double-blind crossover trial. Arch 
Intern Med, 164:514-20.
Wespes E, Amar E, Hatzichristou D, et al. 2006. EAU Guidelines on erectile 
dysfunction: an update. Eur Urol, 49:806-15.
Young JM, Bennett C, Gilhooly P, et al. 2002. Efﬁ  cacy and safety of silde-
naﬁ  l citrate (Viagra) in black and Hispanic American men. Urology, 
60:39-48.
Zippe CD, Kedia AW, Kedia K, et al. 1998. Treatment of erectile dys-
function after radical prostatectomy with sildenaﬁ  l citrate (Viagra). 
Urology, 52:963-6.